At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 195 enrolled
Drug / intervention
Tisotumab Vedotin (HuMax-TF-ADC)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
In Brief
A Phase 2 clinical trial evaluating Tisotumab Vedotin (HuMax-TF-ADC) for Ovary Cancer and 7 related conditions. Completed, enrolled 195 participants across 29 sites in 5 countries.
Detailed Summary
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
CountriesBelgium, Denmark, Sweden, United Kingdom, United States
CollaboratorsGenmab
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionMay 2019
TodayJul 2026
First PostedDec 5, 2013
Enrollment StartNov 30, 2013
Primary CompletionMay 2, 2019
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 12.6 years ago
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)drug